naxagolide has been researched along with Atherosclerotic Parkinsonism in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (41.18) | 18.7374 |
1990's | 10 (58.82) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Martínez-Vila, E | 1 |
Herrero, MT; Laguna, J; Luquin, MR; Obeso, JA | 1 |
Laguna, J; Luquin, MR; Obeso, JA | 1 |
Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ | 1 |
Bédard, PJ; Gomez-Mancilla, B | 1 |
Alexander, GM; Brainard, DL; Gordon, SW; Grothusen, JR; Hichens, M; Schwartzman, RJ | 1 |
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S | 1 |
de Yébenes, JG; Fahn, S; Goodman, R; Jamrosik, Z; Pezzoli, G; Popalski, S | 1 |
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 1 |
Bondi, JV; Hichens, M; Iversen, SD; Jennings, CA; Loper, AE; Rupniak, NM; Stahl, SM; Tye, SJ | 1 |
Bondi, JV; Hand, E; Hichens, M; Iversen, SD; Jennings, CA; Loper, AE; Rupniak, NM; Stahl, SM; Tye, SJ | 1 |
Jenner, P; Marsden, CD; Nomoto, M; Stahl, S | 1 |
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
Gordon, J; Herbster, G; Koller, W | 1 |
de Yebenes, JG; Fahn, S; Jackson-Lewis, V; Mena, MA | 1 |
Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM | 1 |
1 review(s) available for naxagolide and Atherosclerotic Parkinsonism
Article | Year |
---|---|
Neurotoxin-related research: from the laboratory to the clinic.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri | 1992 |
16 other study(ies) available for naxagolide and Atherosclerotic Parkinsonism
Article | Year |
---|---|
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Topics: Animals; Benzazepines; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Indoles; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1994 |
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Drug Tolerance; Female; Macaca fascicularis; Male; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Psychomotor Performance | 1993 |
Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
Topics: Animals; Benzazepines; Dopamine Agents; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Movement Disorders; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D2 | 1992 |
Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Female; Indoles; Macaca fascicularis; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine | 1991 |
Modulatory role for CCK-B antagonists in Parkinson's disease.
Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri | 1990 |
Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; Injections, Intraventricular; Macaca fascicularis; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Rats; Receptors, Dopamine | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.
Topics: Administration, Cutaneous; Animals; Oxazines; Parkinson Disease, Secondary; Saimiri | 1989 |
Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Behavior, Animal; Male; Oxazines; Parkinson Disease, Secondary; Pyridines; Saimiri | 1989 |
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Dopamine Agents; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Pyridines | 1987 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
PHNO, a novel dopamine agonist, in animal models of parkinsonism.
Topics: Animals; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Injections, Subcutaneous; Male; Oxazines; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Infusion Pumps; Injections, Intraventricular; Male; Motor Activity; Neural Pathways; Oxazines; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1987 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines | 1988 |